WEDNESDAY, 16 SEPTEMBER 2026

Bombay High Court rules in favour of Vodafone in tax case

Agencies

Mumbai

The Bombay High Court has ruled in favour of Vodafone in one of a series of tax cases involving the British telecoms company in India, a decision seen as positive for several other firms fighting similar disputes.

The court backed Vodafone's efforts to oppose a move by tax authorities to add Rs 85 billion ($1.3 billion) to the taxable income of a unit, Vodafone India Services Pvt Ltd, which provided call centre services to some group companies.

It had initially received a tax claim of about $600 million.

Vodafone, one of India's largest corporate investors, has repeatedly clashed with the authorities over taxes since it bought Hutchison's mobile business in 2007. It was held liable for capital gains tax which authorities say is owed on the deal.

A dispute over a capital gains tax demand worth more than $2 billion related to that deal has yet to be resolved.

Vodafone's treatment, seen by many investors as heavy-handed, had fuelled debate over India's unpredictable rules and regulations.

The Bombay High Court had separately ruled in favour of the group last year in a transfer pricing tax dispute. In that case, India's tax office had accused Vodafone India Services Pvt Ltd of under-pricing shares in a rights issue to its parent, and had demanded tax of about 30 billion rupees.

The government, seeking to clean up a reputation for "tax terrorism", decided to not appeal that case.

Transfer pricing is the value at which firms trade products, services or assets between units across borders, a regular part of doing business for a multinational.

Several other multinationals including IBM Corp, Royal Dutch Shell Plc and Nokia Oyj are also fighting transfer-pricing cases in India.

Vodafone said in a statement that it welcomed the latest court ruling. It did not comment further.

SHARE ON

Cipla ties up with Serum Institute to sell vaccines in South Africa

The Goan Network
Published Oct 8, 2015, 12:00 AM IST
SHARE ON

Agencies Mumbai Cipla Ltd, India's fourth-largest drugmaker by sales, said on Thursday it had agreed to an exclusive deal with Serum Institute of India to supply vaccines to South Africa, adding a new market to their partnership in India and Europe. Cipla's unit Cipla Medpro, South Africa's third-largest drugs manufacturer, will be responsible for obtaining regulatory approvals and marketing of the vaccines under the deal terms, Cipla said in a statement to exchanges.The…

READ MORE

Keep Reading — More from THE GOAN SPECIAL

3 more related stories queued · tap to continue reading

Home HOME News GOA NEWS Global GLOBAL GOENKAR Search SEARCH